San Juan Oncology Associates

Summary

San Juan Oncology Associates is a medical facility located in Farmington, New Mexico. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Cancer, Multiple Myeloma and other specialties. San Juan Oncology Associates is involved with conducting 60 clinical trials across 94 conditions. There are 3 research doctors associated with this hospital, such as Sardar Imam, Sardar Z Imam, and Jeffrey Neidhart.

Top PIs

Clinical Trials running at San Juan Oncology Associates

Breast Cancer

Lung Cancer

Non-Small Cell Lung Cancer

Stomach Cancer

Myelodysplastic Syndrome

Cancer

Multiple Myeloma

Breast cancer

Stomach Tumors

Gastric Cancer

Sacituzumab Govitecan + Pembrolizumab

for Triple Negative Breast Cancer

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.

Recruiting

2 awards

Phase 3

6 criteria

Disitamab Vedotin + Tucatinib

for Breast Cancer

This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment options for patients with advanced or metastatic solid tumors that express HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab vedotin is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial uses a drug called tucatinib, which has been approved to treat cancer in the United States and some other countries. This drug is sold under the brand name TUKYSA®. This study will test how safe and how well DV with tucatinib works for participants with solid tumors. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.

Recruiting

1 award

Phase 2

6 criteria